161 related articles for article (PubMed ID: 30277446)
1. PD-1 Blockade-induced Inflammatory Arthritis.
Nobashi T; Mittra E
Radiology; 2018 Dec; 289(3):616. PubMed ID: 30277446
[No Abstract] [Full Text] [Related]
2. Pembrolizumab-Related Sarcoid-Like Reaction Presenting as Reactivation of Quiescent Scars.
McKenna MC; Molloy K; Crowther S; Feeney J; Gillis A; Connolly M; Kelleher F
J Oncol Pract; 2018 Mar; 14(3):200-201. PubMed ID: 29300520
[No Abstract] [Full Text] [Related]
3. [Grover's-like drug eruption under anti-PD-1 therapy for metastatic melanoma].
Amini-Adle M; Balme B; Dalle S
Ann Dermatol Venereol; 2018 Dec; 145(12):802-803. PubMed ID: 30415933
[No Abstract] [Full Text] [Related]
4. Squamous cell carcinoma associated with chronic graft versus host disease-like/lichen planus-like lesion of the oral cavity in a patient managed for metastatic melanoma with a PD-1 inhibitor pembrolizumab.
Owosho AA; Randazzo J; Rosen EB; Estilo CL; Huryn JM; Chi P; Yom SK
Oral Oncol; 2016 Dec; 63():e1-e3. PubMed ID: 27743938
[No Abstract] [Full Text] [Related]
5. Vitiligo under anti-programmed cell death-1 therapy is associated with increased survival in melanoma patients.
Nardin C; Jeand'heur A; Bouiller K; Valnet-Rabier MB; Dresco F; Castagna J; Mareschal A; Carlet C; Nerich V; Limat S; Puzenat E; Aubin F
J Am Acad Dermatol; 2020 Mar; 82(3):770-772. PubMed ID: 31734192
[No Abstract] [Full Text] [Related]
6. Pembrolizumab-induced dermatomyositis in a patient with metastatic melanoma.
Berger M; Legeay AL; Souci S; Streichenberger N; Thomas L; Dalle S
Eur J Cancer; 2018 Nov; 104():227-230. PubMed ID: 30322679
[No Abstract] [Full Text] [Related]
7. Pembrolizumab-induced Sarcoid-like Reactions during Treatment of Metastatic Melanoma.
Cheshire SC; Board RE; Lewis AR; Gudur LD; Dobson MJ
Radiology; 2018 Nov; 289(2):564-567. PubMed ID: 30106351
[TBL] [Abstract][Full Text] [Related]
8. Anti-PD-1-associated organizing pneumonia in a responding melanoma patient.
Fiset PO; Shapera S; Butler MO; Tsao MS
Ann Oncol; 2016 Aug; 27(8):1649-50. PubMed ID: 27091805
[No Abstract] [Full Text] [Related]
9. Alemtuzumab for Immune-Related Myocarditis Due to PD-1 Therapy.
Esfahani K; Buhlaiga N; Thébault P; Lapointe R; Johnson NA; Miller WH
N Engl J Med; 2019 Jun; 380(24):2375-2376. PubMed ID: 31189042
[No Abstract] [Full Text] [Related]
10. Resistance to PD-1 blockade in melanoma.
Burki TK
Lancet Oncol; 2016 Sep; 17(9):e376. PubMed ID: 27452143
[No Abstract] [Full Text] [Related]
11. Focal regression of a primary melanoma, fading lentigines and poliosis in metastatic melanoma treated with anti-PD-1.
Thomas S; Laino A; Sturm R; Nufer K; Lambie D; Shepherd B; Atkinson V; Adams L; Soyer HP; Schaider H
J Eur Acad Dermatol Venereol; 2018 May; 32(5):e176-e177. PubMed ID: 29114959
[No Abstract] [Full Text] [Related]
12. An Unusual Case of Synchronous Metastatic Melanomas With Differing Response to Pembrolizumab.
Doolan BJ; McLean C; Mar V; Moore M
J Oncol Pract; 2019 Mar; 15(3):159-160. PubMed ID: 30861362
[No Abstract] [Full Text] [Related]
13. Lichen planus in a patient treated with pembrolizumab for metastatic malignant melanoma.
Denny J; Chong H; Akhras V
Clin Exp Dermatol; 2018 Apr; 43(3):354-356. PubMed ID: 29222829
[No Abstract] [Full Text] [Related]
14. [Treating metastatic melanoma: Risk management].
Lebbe C; Robert C
Ann Dermatol Venereol; 2017 Jan; 144(1):3-5. PubMed ID: 28063593
[No Abstract] [Full Text] [Related]
15. Pembrolizumab for classical Hodgkin's lymphoma.
Burki TK
Lancet Oncol; 2016 Aug; 17(8):e324. PubMed ID: 27397043
[No Abstract] [Full Text] [Related]
16. Checkpoint inhibitor-induced sarcoid reaction mimicking bone metastases.
Jespersen H; Bjursten S; Ny L; Levin M
Lancet Oncol; 2018 Jun; 19(6):e327. PubMed ID: 29893264
[No Abstract] [Full Text] [Related]
17. Lupus-like cutaneous reaction following pembrolizumab: An immune-related adverse event associated with anti-PD-1 therapy.
Shao K; McGettigan S; Elenitsas R; Chu EY
J Cutan Pathol; 2018 Jan; 45(1):74-77. PubMed ID: 29028121
[TBL] [Abstract][Full Text] [Related]
18. Mitochondrial myopathy associated with anti-programmed cell death 1 therapy.
Ibrahim T; Adam C; Routier E; Slama A; Robert C
Eur J Cancer; 2019 Mar; 110():71-73. PubMed ID: 30772655
[No Abstract] [Full Text] [Related]
19. Antiprogrammed Cell Death-1 Immunotherapy-Related Secondary Sclerosing Cholangitis.
Ogawa K; Kamimura K; Terai S
Hepatology; 2019 Feb; 69(2):914-916. PubMed ID: 30033637
[No Abstract] [Full Text] [Related]
20. Fulminant type 1 diabetes mellitus associated with pembrolizumab.
Mizab Mellah C; Sánchez Pérez M; Santos Rey MD; Hernández García M
Endocrinol Diabetes Nutr; 2017 May; 64(5):272-273. PubMed ID: 29056250
[No Abstract] [Full Text] [Related]
[Next] [New Search]
